Morphotek Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 12102018 Prices from USD $250

Morphotek Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12102018] Prices from USD $250

11:52 EDT 17 Oct 2018 | BioPortfolio Report Blog

Summary


Morphotek Inc Morphotek, a subsidiary of Eisai Inc, is a clinicalstage biotechnology company that develops monoclonal antibodies, antibody drug conjugates, and bispecific antibodies to treat cancer, inflammatory and infectious diseases. Its pipeline product portfolio includes farletuzumab, a humanized IgG1 antibody targeting folate receptor alpha FRA for the treatment of ovarian and lung cancers; and amatuximab, a chimeric, IgG1 antibody that targets a cellsurface glycoprotein, mesothelin for treating mesothelioma. Morphotek also provides ontuxizumab targets cellsurface protein, endosialin for the treatment of cancers; gimsilumab against rheumatoid arthritis RA; MORAb202, an antibody drug conjugate ADC for metastatic breast cancer; and MORAb048, MORAb050 and MORAb066 targeting tissue factor TF expressing malignancies. It offers services such as drug discovery and development, GLP and GMP production, antibodies investigation, antibody and protein engineering technologies, and others. The company works in partnership with other biotech companies, research organizations, and academic centers for discovery and development of its pipeline products. Morphotek is headquartered in Exton, Pennsylvania, the US.


Morphotek Inc Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions.


GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.


Scope


Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.

Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.

Business Description A brief description of the company's operations.

Key Employees A list of the key executives of the company.

Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors A list of the key competitors of the company.

Key Recent Developments A brief on recent news about the company.


Reasons to Buy


Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.


Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.


Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.


Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.


Stay uptodate on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.


Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.


Note*: Some sections may be missing if data is unavailable for the company.

More From BioPortfolio on "Morphotek Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12102018] Prices from USD $250"